Merck KGaA (ETR:MRK)
Germany · Delayed Price · Currency is EUR | Market Cap | 65.91B +38.2% |
| Revenue (ttm) | 21.14B -0.4% |
| Net Income | 2.37B -17.2% |
| EPS | 5.45 -17.3% |
| Shares Out | 434.78M |
| PE Ratio | 27.82 |
| Forward PE | 17.80 |
| Dividend | 2.20 (1.45%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 216,344 |
| Open | 149.30 |
| Previous Close | 149.35 |
| Day's Range | 149.30 - 151.60 |
| 52-Week Range | 100.70 - 152.10 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 156.23 (+3.05%) |
| Earnings Date | Nov 12, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry... [Read more]
Full Company ProfileFinancial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is €156.23, which is an increase of 3.05% from the latest price.
News
PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor response with clinically ...
Earnings Preview: Merck KGaA (MKKGY) Q3 Earnings Expected to Decline
Merck KGaA (MKKGY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MilliporeSigma: Merck KGaA, Darmstadt, Germany Hosts Change Chemistry European Forum To Advance Safety and Sustainability in Chemistry
NORTHAMPTON, MA / ACCESS Newswire / November 4, 2026 / Merck KGaA, Darmstadt, Germany, recently hosted Change Chemistry at its global headquarters for the nonprofit organization's 2026 European For...
Lonza to buy five US sites from Merck KGaA
Contract drug manufacturer Lonza said on Tuesday it would buy five US manufacturing sites from Merck KGaA, more than doubling its footprint in the country and expanding its capabilities to produce ad...
Lonza Group To Buy Merck's CDMO Business
(RTTNews) - Lonza Group (LONN.SW, LZAGF.PK) said on Tuesday that it has inked a deal to acquire five contract development and manufacturing organization, CDMO, sites in the U.S. from Merck KGaA (MRCG....
Adhoc: Lonza Group AG: Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence
Lonza Group AG / Key word(s): Acquisition Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence 03-Nov-2026 / 07:05 CET/CE...
Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence
Lonza Group AG / Key word(s): Acquisition Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence 03-Nov-2026 / 07:05 CET/CEST R...
Merck KGaA
MilliporeSigma: 10 Years, 10 Stories: From Curiosity to Career
NORTHAMPTON, MA / ACCESS Newswire / October 30, 2026 / Over the past decade, employees at MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, have turned a ...
EMD Serono: Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years Tumor responses remained robust1 and durable2 Not intended for UK-based media Merck KGaA, Darmstad...
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silence Therapeutics plc (NasdaqGM: SLN) to Me...
Why Merck KGaA Is Paying a 130% Premium for This Gene-Silencing Tech
Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence Therapeutics, more than double the target's closing price as of Friday.
Germany's Merck buys Silence Therapeutics for $1.3 billion
German drugmaker Merck KGaA said on Monday it will acquire Silence Therapeutics in an all-cash deal for about $1.3 billion, adding precision engineered medicines and gene silencing to its portfolio.
Silence Therapeutics plc: Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
All-Cash Transaction Values Silence Therapeutics at Approximately $1.3 Billion Price of $20.00 Per ADS in Cash Represents 130% Premium to Silence's Closing ADS Price on October 16, 2026 Transactio...
EMD Serono: Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset
Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeutics is a UK-headquartered biotechnology comp...
MilliporeSigma Wins Transformation Project of the Year at 2026 Global Sustainability Awards
NORTHAMPTON, MA / ACCESS Newswire / October 16, 2026 / MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has been named the winner of the Transformation P...
Adlai Nortye Partners With Lilly And Merck KGaA To Evaluate AN4035 Combination In Solid Tumors
(RTTNews) - Adlai Nortye Group (ANL) has entered into clinical trial collaboration and supply agreements with Eli Lilly and Company (LLY) and Merck KGaA (MKKGY), Darmstadt, Germany to evaluate its inv...
Adlai To Enter Clinical Trial Collaborations With Lilly, Merck KGaA To Explore Cetuximab With AN4035
INDIANAPOLIS (dpa-AFX) - Adlai Nortye Group (ANL) announced clinical trial collaboration and supply agreements with Eli Lilly and Company (LLY) and Merck KGaA (MRCG.DE, MRK.DE) for the anti-EGFR a...
EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 12.10.2...
Merck KGaA Q2 Earnings Call Highlights
Merck KGaA ETR: MRK reported accelerating organic sales and earnings growth in the second quarter of 2026, led by Life Science and Electronics, and raised its full-year outlook for sales, EBITDA pre a...
Merck KGaA Earnings Call Transcript: Q2 2026
Q2 2026 saw robust organic sales and EBITDA pre growth, led by Life Science and Electronics, with raised full-year guidance reflecting strong momentum. Healthcare faced headwinds from U.S. generic competition, but rare diseases and pipeline progress provided offsets. Bio-Techne acquisition and AI-driven semiconductor demand are key growth drivers.
Merck KGaA Quarterly report: Q2 2026
Merck KGaA has published its Q2 2026 quarterly earnings report on August 6, 2026.
Merck KGaA Earnings release: Q2 2026
Merck KGaA released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Merck KGaA Slides: Q2 2026
Merck KGaA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.